Semorex Technologies — raw details

Highlights

IIA supported (ever)1 patentProfile claimed by owner

About

Cancer Therapeutics and IFI/SFI Diagnostics

Semorex Technologies has discovered molecular compounds that exhibit potent and selective anticancer activity against solid tumors and hematological malignancies. The company is interested in using these compounds, which were found to be nontoxic in mice models, to develop anticancer therapies. Semorex has also developed a diagnostic approach for the rapid and reliable diagnosis of systemic/invasive fungal infection (SFI/IFI). The companys method offers quick and appropriate treatment for patients with fungal infections while ruling out SFI/IFI in individuals suffering from other disease states causing similar symptoms. Semorex Technologies Ltd is an R&D subsidiary of Semorex Inc.

Identity

Name	Semorex Technologies
Slug	semorex-technologies
Type / kind	startup
Crunchbase ID	semorex-technologies
Source _id	agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwNPjs48LDA

Status

Status	inactive
Status reason	Non Active, Jan 2019 ceased to operate
Last update	2026-05-17

Location

HQ country code	IL
HQ region/district	Jerusalem District
HQ city	Jerusalem
HQ address	Shmu'el HaNagid Street 20, Jerusalem, Israel

Web & social

LinkedIn	https://www.linkedin.com/company/8503456

Classifications

Primary sector Health Tech & Life Sciences

Sub-sectors

Health Tech & Life SciencesPharma & Medical BiotechnologyTest Diagnostics & ScreeningDrugs Discovery & Development

Technologies

BiologicalsMolecules

Target customers

Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcareProviders

Business models

B2B

Funding

Total raised	—
Current stage	Pre-Funding

Raw source document

Show full JSON (0 KB)

{
  "0": "s",
  "1": "l",
  "2": "i",
  "3": "m",
  "4": "p",
  "5": "a",
  "6": "g",
  "7": "e",
  "8": "s",
  "9": "_",
  "10": "i",
  "11": "m",
  "12": "p",
  "13": "o",
  "14": "r",
  "15": "t"
}